HUMA

HUMA

Humacyte Inc

Net -139.00%top 1%Rev -1.08%top 1%1Y
Hold

Humacyte develops and manufactures off-the-shelf, bioengineered human tissues for implantable use, targeting vascular repair and reconstruction in various medical applications, including hemodialysis access and treatment for Type 1 diabetes.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$67today

Score Overview

1 Year
Scoreโ€”
Net Growth-139.00%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-1.08%
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-268.59%
Net Trend40%
Net Income Consistency
Rev Growth59.62%
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

Humacyte Inc fundamental performance

Across Humacyte Inc's full reported history, from 2021 to 2025, revenue grew from $ 1M to $ 2M and net income went from -$ 26M to -$ 40M. Revenue increased in 40% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.67โ€”
1 Year2025-08-12
$ 1.79-62.95%
5 Years2021-08-12
$ 9.98-93.34%
All Time2021-08-26
$ 10.96-93.93%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 2M-$ 97M$ 48M
2025$ 2M-$ 40M$ 50M
2024$ 0.00-$ 148M$ 44M
2023$ 0.00-$ 110M$ 80M
2022$ 1M-$ 11M$ 151M
IPO2021$ 1M-$ 26M$ 225M

Explore beyond HUMA

You're looking at Humacyte Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies